@article{ATM6587,
author = {Francis Spinale and Robert Gorman and Jason Burdick},
title = {Author response: new therapies for reducing post-myocardial left ventricular remodeling},
journal = {Annals of Translational Medicine},
volume = {3},
number = {10},
year = {2015},
keywords = {},
abstract = {The need for advancing therapeutic strategies with respect to post myocardial infarction (MI) remodeling and the subsequent prevention to progressive left ventricular (LV) failure was well articulated in the editorial by Kloner and colleagues. Specifically, the editorialists identified the need to focus our attention on how localized delivery of stem cells and other strategies can favorably alter the structure and function of the MI region. In this commentary, reference was made to our study regarding the use of a localized delivery strategy by which a recombinant tissue inhibitor of the matrix metalloproteinases (rTIMP-3) was encapsulated in a degradable hydrogel biomaterial and injected directly into the MI region of pigs. In this study, we developed a method by which rTIMP-3 would continuously elute into the MI region with no detectable release into adjacent viable myocardium or the systemic circulation. The key findings were that rTIMP-3 release into the newly formed MI region attenuated key indices of adverse LV remodeling and failure, which included a reduction in LV dilation and pulmonary capillary wedge pressure. At the cellular/molecular level, rTIMP-3 release into the MI region reduced indices of inflammation, such as cytokine expression and macrophage polarization. This was the first study to demonstrate that localized release of a recombinant TIMP could alter the natural history of post- MI remodeling. These findings provide additional evidence that targeting the MMP system in the post-MI context is a relevant therapeutic target.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/6587}
}